AR076332A1 - Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. - Google Patents
Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.Info
- Publication number
- AR076332A1 AR076332A1 ARP100101291A ARP100101291A AR076332A1 AR 076332 A1 AR076332 A1 AR 076332A1 AR P100101291 A ARP100101291 A AR P100101291A AR P100101291 A ARP100101291 A AR P100101291A AR 076332 A1 AR076332 A1 AR 076332A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrere
- nrcrc
- nrgrg
- nrg
- org
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Reivindicacion 1: Compuestos caracterizados porque tienen la formula general (1), en la que R1 y R4 independientemente entre sí representan un grupo seleccionado entre Ra, Rb y Ra sustituido con uno o más Rb y/o Rc iguales o diferentes; o un R1 junto con la piridina forma un anillo heteroarilo de 9-10 miembros, que está opcionalmente sustituido con uno o más Rb y/o Rc iguales o diferentes y R2 y R3 independientemente entre sí representan un grupo seleccionado entre alquilo C1-6, cicloalquilo C3-8, heterocicloalquilo de 3-8 miembros, arilo C6-10 y heteroarilo de 5-12 miembros, opcionalmente sustituido con uno o más R5 iguales o diferentes y cada R5 representa un grupo seleccionado entre Ra, Rb y Ra sustituido con uno o más Rb y/o Rc iguales o diferentes; y cada Ra independientemente de cualquier otro representa un grupo opcionalmente sustituido con uno o más Rb y/o Rc iguales o diferentes, seleccionados entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, cada Rb representa un grupo adecuado y se selecciona independientemente de cualquier otro entre =O, -ORc, haloalquiloxi C1-3, -OCF3, =S, -SRc, =NRc, =NORc, =NNRcRc, =NN(Rg)C(O)NRcRc, -NRcRc, -ONRcRc, -N(ORc)Rc, -N(Rg)NRcRc, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Rc, -S(O)ORc, -S(O)2Rc, -S(O)2ORc, -S(O)NRcRc, -S(O)2NRcRc, -OS(O)Rc, -OS(O)2Rc, -OS(O)2ORc, -OS(O)NRcRc, -OS(O)2NRcRc, -C(O)Rc, -C(O)ORc, -C(O)SRc, -C(O)NRcRc, -C(O)N(Rg)NRcRc, -C(O)N(Rg)ORc, -C(NRg)NRcRc, -C(NOH)Rc, -C(NOH)NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)SRc, -OC(O)NRcRc, -OC(NRg)NRcRc, -SC(O)Rc, -SC(O)ORc, -SC(O)NRcRc, -SC(NRg)NRcRc, -N(Rg)C(O)Rc, -N[C(O)Rc]2, -N(ORg)C(O)Rc, -N(Rg)C(NRg)Rc, -N(Rg)N(Rg)C(O)Rc, -N[C(O)Rc]NRcRc, -N(Rg)C(S)Rc, -N(Rg)S(O)Rc, -N(Rg)S(O)ORc, -N(Rg)S(O)2Rc, -N[S(O)2Rc]2, -N(Rg)S(O)2ORc, -N(Rg)S(O)2NRcRc, -N(Rg)[S(O)2]2Rc, -N(Rg)C(O)ORc, -N(Rg)C(O)SRc, -N(Rg)C(O)NRcRc, -N(Rg)C(O)NRgNRcRc, -N(Rg)N(Rg)C(O)NRcRc, -N(Rg)C(S)NRcRc, -[N(Rg)C(O)]2Rc, -N(Rg)[C(O)]2Rc, -N{[C(O)2]Rc}2, -N(Rg)[C(O)]2ORc, -N(Rg)[C(O)]2NRcRc, -N{[C(O)]2ORc}2, -N{[C(O)]2NRcRc}2, -[N(Rg)C(O)]2ORc, -N(Rg)C(NRg)ORc, -N(Rg)C(NOH)Rc, -N(Rg)C(NRg)SRc, -N(Rg)C(NRg)NRcRc y -N=C(Rg)NRcRc y cada Rc independientemente de cualquier otro representa hidrogeno o un grupo opcionalmente sustituido con uno o más Rd y/o Re iguales o diferentes, seleccionados entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, y cada Rd representa un grupo adecuado y se selecciona independientemente de cualquier otro entre =O, -ORe, haloalquiloxi C1-3, -OCF3, =S, -SRe, =NRe, =NORe, =NNReRe, =NN(Rg)C(O)NreRe, -NReRe, -ONReRe, -N(Rg)NReRe, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Re, -S(O)ORe, -S(O)2Re, -S(O)2ORe, -S(O)NReRe, -S(O)2NReRe, -OS(O)Re, -OS(O)2Re, -OS(O)2ORe, -OS(O)NReRe, -OS(O)2NReRe, -C(O)Re, -C(O)ORe, -C(O)SRe, -C(O)NReRe, -C(O)N(Rg)NReRe, -C(O)N(Rg)ORe, -C(NRg)NReRe, -C(NOH)Re, -C(NOH)NReRe, -OC(O)Re, -OC(O)ORe, -OC(O)SRe, -OC(O)NReRe, -OC(NRg)NReRe, -SC(O)Re, -SC(O)ORe, -SC(O)NReRe, -SC(NRg)NReRe, -N(Rg)C(O)Re, -N[C(O)Re]2, -N(ORg)C(O)Re, -N(Rg)C(NRg)Re, -N(Rg)N(Rg)C(O)Re, -N[C(O)Re]NReRe, -N(Rg)C(S)Re, -N(Rg)S(O)Re, -N(Rg)S(O)ORe, -N(Rg)S(O)2Re, -N[S(O)2Re]2, -N(Rg)S(O)2ORe, -N(Rg)S(O)2NReRe, -N(Rg)[S(O)2]2Re, -N(Rg)C(O)ORe, -N(Rg)C(O)SRe, -N(Rg)C(O)NReRe, -N(Rg)C(O)NRgNReRe, -N(Rg)N(Rg)C(O)NReRe, -N(Rg)C(S)NReRe, -[N(Rg)C(O)]2Re, -N(Rg)[C(O)]2Re, -N{[C(O)2]Re}2, -N(Rg)[C(O)]2ORe, -N(Rg)[C(O)]2NReRe, -N{[C(O)]2ORe}2, -N{[C(O)]2NReRe}2, -[N(Rg)C(O)]2ORe, -N(Rg)C(NRg)ORe, -N(Rg)C(NOH)Re, -N(Rg)C(NRg)SRe, -N(Rg)C(NRg)NReRe y -N=C(Rg)NReRe, cada Re independientemente de cualquier otro representa hidrogeno o un grupo opcionalmente sustituido con uno o más Rf y/o Rg iguales o diferentes, seleccionados entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros, y cada Rf representa un grupo adecuado y en cada caso se selecciona independientemente de cualquier otro entre =O, -ORg, haloalquiloxi C1-3, -OCF3, =S, -SRg, =NRg, =NORg, =NNRgRg, =NN(Rh)C(O)NRgRg, -NRgRg, -ONRgRg, -N(Rh)NRgRg, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Rg, -S(O)ORg, -S(O)2Rg, -S(O)2ORg, -S(O)NRgRg, -S(O)2NRgRg, -OS(O)Rg, -OS(O)2Rg, -OS(O)2ORg, -OS(O)NRgRg, -OS(O)2NRgRg, -C(O)Rg, -C(O)ORg, -C(O)SRg, -C(O)NRgRg, -C(O)N(Rh)NRgRg, -C(O)N(Rh)ORg, -C(NRh)NRgRg, -C(NOH)Rg, -C(NOH)NRgRg, -OC(O)Rg, -OC(O)ORg, -OC(O)SRg, -OC(O)NRgRg, -OC(NRh)NRgRg, -SC(O)Rg, -SC(O)ORg, -SC(O)NRgRg, -SC(NRh)NRgRg, -N(Rh)C(O)Rg, -N[C(O)Rg]2, -N(ORh)C(O)Rg, -N(Rh)C(NRh)Rg, -N(Rh)N(Rh)C(O)Rg, -N[C(O)Rg]NRgRg, -N(Rh)C(S)Rg, -N(Rh)S(O)Rg, -N(Rh)S(O)ORg, -N(Rh)S(O)2Rg, -N[S(O)2Rg]2, -N(Rh)S(O)2ORg, -N(Rh)S(O)2NRgRg, -N(Rh)[S(O)2]2Rg, -N(Rh)C(O)ORg, -N(Rh)C(O)SRg, -N(Rh)C(O)NRgRg, -N(Rh)C(O)NRhNRgRg, -N(Rh)N(Rh)C(O)NRgRg, -N(Rh)C(S)NRgRg, -[N(Rh)C(O)]2Rg, -N(Rh)[C(O)]2Rg, -N{[C(O)2]Rg}2, -N(Rh)[C(O)]2ORg, -N(Rh)[C(O)]2NRgRg, -N{[C(O)]2ORg}2, -N{[C(O)]2NRgRg}2, -[N(Rh)C(O)]2ORg, -N(Rh)C(NRh)ORg, -N(Rh)C(NOH)Rg, -N(Rh)C(NRh)SRg, -N(Rh)C(NRh)NRgRg y -N=C(Rh)NRhRh, y cada Rg, de manera independiente entre sí, significa hidrogeno o un grupo opcionalmente sustituido con uno o más Rh iguales o diferentes, seleccionados entre alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros; y cada Rh se selecciona independientemente de cualquier otro entre hidrogeno, alquilo C1-6, heteroalquilo de 2-6 miembros, haloalquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroarilo de 5-12 miembros, heteroarilalquilo de 6-18 miembros, heterocicloalquilo de 3-14 miembros y heterocicloalquilalquilo de 4-14 miembros; y m representa 0, 1 o 2; y n representa 0, 1,2 o 3; y opcionalmente en forma de los profármacos, los tautomeros, los racematos, los enantiomeros, los diastereomeros, los profármacos y las mezclas de los mismos, y opcionalmente las sales farmacologicamente aceptables de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09158327 | 2009-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076332A1 true AR076332A1 (es) | 2011-06-01 |
Family
ID=40719954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101291A AR076332A1 (es) | 2009-04-21 | 2010-04-19 | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20110098275A1 (es) |
EP (1) | EP2421846B1 (es) |
JP (1) | JP5635592B2 (es) |
KR (1) | KR20120004529A (es) |
CN (1) | CN102459224A (es) |
AP (1) | AP2011005894A0 (es) |
AR (1) | AR076332A1 (es) |
AU (1) | AU2010240963A1 (es) |
BR (1) | BRPI1013716A2 (es) |
CA (1) | CA2759368A1 (es) |
CL (1) | CL2011002625A1 (es) |
CO (1) | CO6460762A2 (es) |
EA (1) | EA201101517A1 (es) |
EC (1) | ECSP11011454A (es) |
IL (1) | IL215161A0 (es) |
MA (1) | MA33222B1 (es) |
MX (1) | MX2011011021A (es) |
PE (1) | PE20120637A1 (es) |
SG (1) | SG175272A1 (es) |
TN (1) | TN2011000531A1 (es) |
TW (1) | TW201103905A (es) |
UY (1) | UY32565A (es) |
WO (1) | WO2010122069A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG184767A1 (en) | 2009-03-23 | 2012-10-30 | Glenmark Pharmaceuticals Sa | Furopyrimidinedione derivatives as trpa1 modulators |
EP2708538B1 (en) | 2009-03-23 | 2015-08-12 | Glenmark Pharmaceuticals S.A. | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators |
US8466162B2 (en) * | 2011-01-26 | 2013-06-18 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyridines |
WO2013177092A1 (en) * | 2012-05-23 | 2013-11-28 | Sunshine Lake Pharma Co., Ltd. | Substituted alkynyl pyridine compounds and methods of use |
ES2838573T3 (es) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
JP2019527725A (ja) * | 2016-08-15 | 2019-10-03 | パデュー リサーチ ファウンデイション | 4位置換アミノイソキノリン誘導体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA85087C2 (en) * | 2004-04-23 | 2008-12-25 | Бристол-Майэрс Сквибб Компани | Monocyclic heterocycles as kinase inhibitors |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
WO2006082373A1 (en) | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
CA2669704A1 (en) * | 2006-11-16 | 2008-05-22 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
PE20110196A1 (es) | 2008-07-29 | 2011-04-03 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas |
JPWO2010024258A1 (ja) * | 2008-08-29 | 2012-01-26 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環アゾール誘導体 |
-
2010
- 2010-04-19 AR ARP100101291A patent/AR076332A1/es unknown
- 2010-04-20 TW TW099112383A patent/TW201103905A/zh unknown
- 2010-04-20 US US12/763,434 patent/US20110098275A1/en not_active Abandoned
- 2010-04-21 WO PCT/EP2010/055293 patent/WO2010122069A1/en active Application Filing
- 2010-04-21 UY UY0001032565A patent/UY32565A/es not_active Application Discontinuation
- 2010-04-21 KR KR1020117027573A patent/KR20120004529A/ko not_active Application Discontinuation
- 2010-04-21 CA CA2759368A patent/CA2759368A1/en not_active Abandoned
- 2010-04-21 BR BRPI1013716A patent/BRPI1013716A2/pt not_active Application Discontinuation
- 2010-04-21 MA MA34283A patent/MA33222B1/fr unknown
- 2010-04-21 CN CN2010800276562A patent/CN102459224A/zh active Pending
- 2010-04-21 MX MX2011011021A patent/MX2011011021A/es not_active Application Discontinuation
- 2010-04-21 EA EA201101517A patent/EA201101517A1/ru unknown
- 2010-04-21 AU AU2010240963A patent/AU2010240963A1/en not_active Abandoned
- 2010-04-21 JP JP2012506482A patent/JP5635592B2/ja active Active
- 2010-04-21 SG SG2011076429A patent/SG175272A1/en unknown
- 2010-04-21 EP EP10714016.2A patent/EP2421846B1/en active Active
- 2010-04-21 AP AP2011005894A patent/AP2011005894A0/xx unknown
- 2010-04-21 PE PE2011001817A patent/PE20120637A1/es not_active Application Discontinuation
-
2011
- 2011-09-15 IL IL215161A patent/IL215161A0/en unknown
- 2011-10-20 TN TNP2011000531A patent/TN2011000531A1/en unknown
- 2011-10-20 CL CL2011002625A patent/CL2011002625A1/es unknown
- 2011-11-11 EC EC2011011454A patent/ECSP11011454A/es unknown
- 2011-11-11 CO CO11154179A patent/CO6460762A2/es not_active Application Discontinuation
-
2013
- 2013-03-12 US US13/795,722 patent/US9090564B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2011011021A (es) | 2011-11-02 |
TW201103905A (en) | 2011-02-01 |
EP2421846B1 (en) | 2016-01-06 |
TN2011000531A1 (en) | 2013-05-24 |
JP5635592B2 (ja) | 2014-12-03 |
UY32565A (es) | 2010-11-30 |
US20110098275A1 (en) | 2011-04-28 |
AU2010240963A1 (en) | 2011-10-13 |
US9090564B2 (en) | 2015-07-28 |
AP2011005894A0 (en) | 2011-10-31 |
EA201101517A1 (ru) | 2012-05-30 |
CA2759368A1 (en) | 2010-10-28 |
IL215161A0 (en) | 2011-12-29 |
MA33222B1 (fr) | 2012-04-02 |
CL2011002625A1 (es) | 2012-04-20 |
BRPI1013716A2 (pt) | 2016-04-05 |
SG175272A1 (en) | 2011-11-28 |
CO6460762A2 (es) | 2012-06-15 |
EP2421846A1 (en) | 2012-02-29 |
KR20120004529A (ko) | 2012-01-12 |
CN102459224A (zh) | 2012-05-16 |
ECSP11011454A (es) | 2011-12-30 |
WO2010122069A1 (en) | 2010-10-28 |
JP2012524750A (ja) | 2012-10-18 |
US20130196975A1 (en) | 2013-08-01 |
PE20120637A1 (es) | 2012-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078513A1 (es) | Pirimidinas y composiciones farmaceuticas que las comprenden | |
AR076134A1 (es) | Derivados de 2,4 diaminopirimidinas | |
AR074210A1 (es) | Derivados de pirimidina como inhibidores de ptk2-quinasa | |
AR072845A1 (es) | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. | |
AR074209A1 (es) | Derivados de pirimidina utiles para el tratamiento del cancer | |
AR076332A1 (es) | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. | |
AR074127A1 (es) | 2,4 diaminopirimidinas y uso para la preparacion de un medicamento para el tratamiento de cancer, infecciones y enfermedades inflamatorias y autoinmunes | |
AR051743A1 (es) | Tiazolil - dihidro- indazoles | |
AR076620A1 (es) | 2,4 DIAMINOPIRIMIDINAS, COMPOSICIONES FARMACEUTICAS, PROCESOS DE PREPARACIoN Y SU USO COMO MEDICAMENTO. | |
AR066963A1 (es) | Derivados de indolinona, preparaciones farmaceuticas que los contienen y usos de los mismos para el tratamiento y/o prevencion de cancer y enfermedades inflamatorias y autoinmunes. | |
AR082850A1 (es) | Aminopirazoloquinazolinas | |
AR080020A1 (es) | 5-alquinil-pirimidinas | |
AR073501A1 (es) | Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa | |
AR072538A1 (es) | Derivados de indolinonas, composiciones farmacéuticas y usos | |
PH12016501632A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
CU20160167A7 (es) | Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias | |
AR057423A1 (es) | 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento | |
ES2722048T3 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
ECSP15045801A (es) | Inhibidores de la phd de 6(5hidroxi1hpirazol1il)nicotinamida | |
AR073700A1 (es) | Heterociclos y composiciones farmaceuticas para usarse en el tratamiento de cancer, infecciones y enfermedades autoinmunitarias | |
AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
AR104642A1 (es) | Compuestos carboximidamida derivados de bencimidazol e imidazopiridina | |
AR070877A1 (es) | Tiazolil-dihidro-indazoles, una preparacion farmaceutica en base al compuesto y uso del compuesto para preparar un medicamento | |
AR084444A1 (es) | Oxindolpirimidinas bencilicas y las preparaciones farmaceuticas que las contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |